When and not if, IMU will be the same.....DYOR (thoroughly this time). The accuracy only need to be better or equal to the current process which is always the case with ResAppDx, hence those peer review medical journals.
- Forums
- ASX - By Stock
- RAP
- Ann: Pfizer raises scheme consideration to A$0.208 per share
Ann: Pfizer raises scheme consideration to A$0.208 per share, page-30
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)